This innovation introduces a novel coacervate protein delivery system that significantly enhances wound healing and tissue repair.
Description
By utilizing both synthetic and natural polymers, this system extends the half-lives of therapeutic proteins from minutes to several weeks, reducing the required dosage and associated costs. This innovation leverages platelet-rich plasma, an FDA-approved protein source, to deliver a complex array of proteins that cannot be synthetically replicated, offering a more effective and affordable solution for various medical applications.
Applications
• Wound Healing
• Myocardial Infarction
• Cartilage Regeneration
• Surgical Trauma
Advantages
This invention offers several advantages over existing protein therapies. The coacervate protein delivery system extends the half-lives of proteins from minutes to several weeks, significantly reducing the required dosage and associated costs. The use of platelet-rich plasma as a protein source is both cost-effective and clinically approved, eliminating the need for expensive recombinant protein production. Additionally, the ability to deliver a complex array of proteins simultaneously enhances the therapeutic efficacy, as these proteins work synergistically to promote healing. For example, the combination of VEGF and KGF in the coacervate system has shown to improve wound healing more effectively than individual protein therapies. This system also minimizes adverse side effects by reducing the frequency and quantity of protein administration.
Invention Readiness
The technology is currently at the in vivo data stage, demonstrating its efficacy in animal models. The next steps involve further preclinical testing to validate the safety and effectiveness of the coacervate protein delivery system in various medical applications. The use of FDA-approved platelet-rich plasma as a protein source accelerates the regulatory approval process, making this invention closer to clinical application. Future development will focus on optimizing the delivery system for different therapeutic proteins and expanding its use to other tissue repair applications.
IP Status
https://patents.google.com/patent/US11857631B2
